Product News and Recalls

Seven Studies now Show Drospirenone (Yaz/Yasmin/Beyaz) increase risk of clots

The most recent independent study was published today in the Canadian Medical Journal

The Canadian Medical Journal published an article today by Dr. Gronich from the Department of Community Medicine and Epidemiology, looking at approximately 330,000 women taking various birth control pills. Overall, they found that drospirenone, an ingredient in Yaz, Yasmin, Ocella, and Beyaz, had a 65% increased risk of causing blood clots when compared more established birth control pills, such as those containing levonorgestrel.

If you suffered a blood clot, pulmonary embolism, or stroke, while on Yaz, contact us to discuss your options for pursuing compensation, or have your questions answered by a qualified attorney, with no obligation. Lopez McHugh currently has a bellwether case being prepared for trial–it may be one of the first in the nation to be tried in the Yaz litigation.

Even before this study was published, the FDA announced that it will hold hearings next month to consider the risks of blood clots associated with Yaz, Yasmin, Ocella, and Beyaz. Now approximately seven studies suggest an increased risk, but the FDA has not yet declared its position. The agency is widely expected to make an announcement at or shortly after the hearings to be held on December 8, 2011.

Yaz contains a compound created by Bayer called drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body. Side effects include heart attack, stroke, pulmonary embolism, blood clots, and even death.